Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jo Shorthouse
Emerging Company Profile: With a Phase I clinical trial starting in Q3 and Series A funding to raise, HOX Therapeutics is taking a step out of the shadows of academia to develop its novel drug candidates in brain and prostate cancer. CEO Karl Keegan spoke to Scrip about what is next for the UK company.
In its latest TANGO trial for chronic lower back pain, Eli Lilly and Pfizer’s tanezumab has shown efficacy at 10 mg, but its 5 mg dose missed the statistically significant mark. Vitally, analysts are encouraged by safety data.
IQVIA has impressed industry observers with its Q4 results, which show the potential of the freshly merged company, especially in its technology division. With biotech money and strategic outsourcing as prevalent as it has been in recent memory, could the rest of the CRO industry follow suit?
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
With four new entrants readying to be prescribed in the next four years, the market for diabetic nephropathy is looking more buoyant than ever. However, competition from GLP-1 agonists and eventually from generics could put a dampener on proceedings.
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.